BS_5P3CZQV8
Neurofibroma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Neurofibroma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Neurofibroma
- overall_survival_months
- 32.35873850197109
- age_years
- 12.636
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_D4PJYHZ2 | Neurofibroma | — | 0.953 |
| 2 | SRR2689710 | — | — | 0.916 |
| 3 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.916 |
| 4 | BS_FQX1PRAJ | Neurofibroma | — | 0.916 |
| 5 | BS_Z28VKGNS | Neurofibroma | — | 0.915 |
| 6 | BS_GDHH6T5A | Neurofibroma | — | 0.915 |
| 7 | 7c6f92ab-6cf8-4293-b676-2619c40f6ee6 | — | — | 0.914 |
| 8 | BS_69V8P8A0 | Neurofibroma | — | 0.912 |
| 9 | 7f51ff28-397d-466f-82b0-25e9c9182ea7 | — | — | 0.911 |
| 10 | MDT-AP-1125 | Med | Medulloblastoma | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.478 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.396 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.393 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.387 | Inavolisib | — uncovered |
| MYOGENESIS | 0.379 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.354 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.335 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.325 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.315 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.311 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.285 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.263 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.254 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.252 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.233 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.231 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.221 | Inavolisib | — uncovered |